Navigation Links
Partnership of academic centers and community hospitals effective model for disseminating advances
Date:5/15/2008

CHICAGO -- A quality-control audit of community hospitals associated with Fox Chase Cancer Center in Philadelphia suggests that a partnership between a major academic cancer center, where most new treatment protocols are created, and community hospitals, where most care is provided, is a highly effective model for quickly and effectively disseminating advances in cancer treatment.

Fox Chase, an NCI-designated Comprehensive Cancer Center in Philadelphia, first established its network of 26 select hospitals in 1986. The Fox Chase Cancer Center Partners program is based on a strong foundation of cancer research and education in the community. A strong feature of the program is the access Partner hospitals have to the most advanced cancer treatment guidelines developed by Fox Chase and other member institutions of the National Comprehensive Cancer Network (NCCN).

"When research leads to significant changes in treatment, it can take years before community oncologists are able to fully adopt the new guidelines. What's unique about the Partners program is the timely translation of advances," said Margaret O'Grady, R.N., M.S.N., O.C.N., Director of Care Management and Clinical Operations of Fox Chase Cancer Center Partners. "The audit we conducted shows that our Partner physicians are highly compliant in incorporating recent advances in cancer treatment."

O'Grady and her team reviewed the medical charts of 124 patients at least 65 years or older treated for stage III colon cancer at Partner hospitals between 2003 and 2006. They checked for documentation compliance regarding recent advancements in the treatment of colon cancer according to treatment guidelines published by the NCCN. Specifically, the advances included increased awareness of obtaining a minimum of 12 lymph nodes at surgery, and the addition of oxaliplatin to adjuvant chemotherapy.

Compliance with NCCN guidelines for documentation was high: staging (98 percent), pathology report (91 percent), colonoscopy (75 percent and 58 percent reaching cecum), CEA (91 percent), CT abdomen/pelvis (93 percent), and chest imaging (100 percent). Activities of daily living were documented commonly (83 percent).

Nearly all patients (123/124) received adjuvant chemotherapy, although only 76 (61 percent) received oxaliplatin, a chemotherapeutic shown to extend the survival in this patient population.

"At first glance, this number looked low, but as we probed further, we found that all but 11 patients who didn't receive oxaliplatin had documented co-morbidities or other concerns that precluded them from receiving this treatment," explained O'Grady.

Thus, community medical oncologists were aware of data suggesting benefit of oxaliplatin, and documented reasoning for patients not receiving it. Whether elderly patients with stage III colon cancer are generally being undertreated requires further study.

The most common chemotherapy regimens administered were FOLFOX (54 percent), bolus 5-FU/LV (19 percent), and capecitabine (12 percent).

"Our audit also found a high rate of lymph node retrieval. This is critically important to medical oncology treatment planning," O'Grady said.

The records indicated that 74 percent of the patients had at least 12 lymph nodes retrieved. Nearly all patients (93 percent) received appropriate surveillance with history and physical exams at suggested intervals and routine CEA testing. Abdominal and pelvic surveillance CT was performed in 78 percent of patients.

"We found a drop off in compliance regarding the documentation of discussions between the doctor and patient about age and life expectancy in relation to adjuvant chemotherapy," said O'Grady. "This discussion is important and informs decision making."

Discussions about life expectancy and a patient's age were documented in only 49 percent of the cases.

"Further research should focus on targeted education efforts in these areas and assessment of their impact," O'Grady concluded.


'/>"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
414-312-7085
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
4. B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership
5. NASN Joins Partnership to Fight Chronic Disease
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
8. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
9. Partnership to Fight Chronic Disease Announces Ideas for Change in Health Care
10. Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement
11. Anthem Blue Cross and Blue Shield Partnership Plan Wins Nevada Immunization Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... today announced it will co-exhibit with technology partners LG Business Solutions at ... Marriott Metro Center in Washington D.C., will provide education and examination into the ...
(Date:3/27/2017)... ... 2017 , ... M&S Technologies, the first name in computerized ... System® 20/20. CE Certification builds upon M&S's long-standing commitment to products and software ... ISO and proven test methods used in the field of Vision Care. Smart ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
(Date:3/27/2017)... ... ... Schloz is still in shock after receiving a $2,500 Academic Award from California Casualty ... said. , She thinks the coming week is going to be a very joyful for ... help my students.” , The award will allow the 4th grade teacher at Tumwater Hill ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017 Summary ... understand Bayer and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... new survey from the American Association of ... (CBP) significantly reduced beneficiary choice and access to commonly ... beneficiaries to switch to unfamiliar or unsuitable testing systems, ... AADE,s survey is the latest in a continuous round ... inherent problems with the CBP. Last year, a National ...
Breaking Medicine Technology: